How should a research site prepare for an FDA inspection?

An FDA investigator may ask, at reasonable times, to access, copy and verify the clinical investigator's records, so a site is ready when its records are complete, current and retrievable on the day, not after (21 CFR 312.68).

Inspectors usually compare consent, eligibility, safety reporting, investigational product and delegation records against the source, so the best preparation is a self-check of those records against ICH E6(R3) and the protocol before anyone asks.

What the regulations require of the site

  • Permit inspection by the regulatory authority and monitoring and auditing by the sponsor (ICH E6(R3) 2.3.5).
  • Make all requested trial records available for direct access (ICH E6(R3) 2.12.14).
  • Keep adequate and accurate case histories, including signed consent forms and medical records, that show consent came before participation (21 CFR 312.62(b)).
  • Keep records of the disposition of the drug: dates, quantities and use by subjects (21 CFR 312.62(a)).

A self-check before the inspector arrives

  • Consent: the right version, signed and dated before any procedure, with the process documented, for every participant.
  • Eligibility: each criterion supported by source, reviewed by the investigator.
  • Safety: every serious adverse event sent to the sponsor on time, with follow up (ICH E6(R3) 2.7.2(b)).
  • Investigational product: accountability that reconciles, and temperature records with excursions handled.
  • Delegation and training: everyone who did a task was delegated and trained before they did it (ICH E6(R3) 2.3.2).
  • Deviations: all documented, the important ones explained with preventive actions (ICH E6(R3) 2.5.3).

What a Form 483 is

At the end of an inspection the FDA investigator may issue a Form FDA 483 listing inspectional observations. A written response, usually prompt, that explains the root cause and the corrective and preventive actions is the site's chance to show the problem is understood and fixed.

Questions people also ask

Does an FDA inspector need participant names?

Usually not. The investigator is not required to reveal subject names unless particular records need more detailed study or there is reason to doubt the records (21 CFR 312.68).

Can an inspection be remote?

Some aspects of an inspection may be conducted remotely (ICH E6(R3) Glossary).

What is the difference between an audit and an inspection?

An audit is an independent examination by the sponsor, a CRO or the institution; an inspection is an official review by a regulatory authority (ICH E6(R3) Glossary).

How can a site practice for an inspection?

Run a mock review of a few participant files against the checklist above, and have staff practice the decisions inspectors probe most, such as consent and safety reporting.

Primary sources

  • 21 CFR 312.68: Inspection of investigator's records and reports (eCFR): https://www.ecfr.gov/current/title-21/section-312.68
  • 21 CFR 312.62: Investigator recordkeeping and record retention (eCFR): https://www.ecfr.gov/current/title-21/section-312.62
  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf

Last reviewed

2026-11-12